In a report released today, Matthew Luchini from BMO Capital maintained a Buy rating on NGM Biopharmaceuticals (NGM), with a price target of ...
The post BMO Capital Sticks to Their Buy Rating for NGM Biopharmaceuticals (NGM) appeared first on Smarter Analyst.
In a report released today, Matthew ...

https://www.smarteranalyst.com/new-blurbs/bmo-capital-sticks-to-their-buy-rating-for-ngm-biopharmaceuticals-ngm/

#SmarterAnalyst